Background: Somatic genomic testing is recommended by numerous expert guidelines to
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …

Purpose: Complete and timely tissue genotyping is challenging, leading to significant
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …

Purpose Treatment guidelines for advanced non–small-cell lung cancer (aNSCLC)
recommend broad molecular profiling for targeted therapy selection. This study …

Objectives Genotype-guided personalized therapy has become an essential part of routine
clinical care in non-small cell lung cancer (NSCLC) patients. However, small tissue …

Introduction: Molecular profiling of tumor tissue is the gold standard for treatment decision-
making in advanced non-small cell lung cancer (NSCLC). Results may be delayed or …

Comprehensive genomic profiling for advanced non-small cell lung cancer (NSCLC) can
identify patients for molecularly targeted therapies that improve clinical outcomes. We …

PURPOSE To assess the feasibility and utility of circulating tumor DNA (ctDNA) by amplicon-
based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of …

Importance The clinical implications of adding plasma-based circulating tumor DNA next-
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …

Introduction Next-generation sequencing (NGS) of cell-free circulating tumor DNA (cfDNA)
enables noninvasive genomic analysis of NSCLC patients. Although plasma-detected …

Objectives Liquid biopsy and comprehensive genomic profiling (CGP) of circulating tumor
DNA (ctDNA) are increasingly used for detection of targetable genomic alterations (GA) in …